Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Brain Neoplasms 11Glioblastoma 3Small Cell Lung Carcinoma 2Neoplasm Metastasis 2Lung Neoplasms 2Recurrence 1Neurotoxicity Syndromes 1Neoplasms, Germ Cell and Embryonal 1Melanoma 1Gliosarcoma 1Gastrointestinal Neoplasms 1Epilepsy 1Ependymoma 1Craniopharyngioma 1Cognitive Dysfunction 1Central Nervous System Neoplasms 1Central Nervous System Carcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Patient Reported Outcome Measures 2Neuropsychological Tests 2lithium sulfate 1XENP 1595 1Tablets 1Sodium Chloride 1Ramipril 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Quality of Life 1Pioglitazone 1Metformin 1Mental Status and Dementia Tests 1Memantine 1Lithium 1G(M1) Ganglioside 1Donepezil 1Climate Anxiety 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cognitive Dysfunction × Memantine × CNS × Clear all
NCT02360215 2025-04-23

Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases

NRG Oncology

Phase 3 Completed
518 enrolled 40 charts
CNS

Brain Neoplasms, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡